Adipogen/Ruxolitinib . phosphate salt/AG-CR1-3645-M025/25 mg
商品编号：
AG-CR1-3645-M025
品牌：
Adipogen Inc
市场价：
¥1900.00
美元价：
1140.00
产品分类：
其他试剂
公司分类：
Other_reagents
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
| ProductDetails | |
|---|---|
| Synonyms | INCB018424;INC424 |
| ProductType | Chemical |
| Properties | |
| Formula | C17H18N6.H3O4P |
| MW | 306.4.98.0 |
| CAS | 1092939-17-7 |
| PurityChemicals | ≥98%(HPLC) |
| Appearance | Whitetooff-whitesolid. |
| Solubility | SolubleinDMSO(>100mg/ml)andwater(8mg/ml).Slightlysolublein100%ethanol. |
| Identity | Determinedby1H-NMRandMS. |
| InChiKey | JFMWPOCYMYGEDM-XFULWGLBSA-N |
| ShippingandHandling | |
| Shipping | AMBIENT |
| ShortTermStorage | +4°C |
| LongTermStorage | -20°C |
| HandlingAdvice | Keepcoolanddry. |
| Use/StABIlity | Stableforatleast2yearsafterreceiptwhenstoredat-20°C. |
| Documents | |
| MSDS |  DownloadPDF |
| ProductSpecificationSheet | |
| Datasheet | DownloadPDF |
- Water-solublephosphatesaltofRuxolitinib.
- Antineoplastic,anti-inflammatoryandimmunomodulatingagent.
- OrallybioavailablepotentATPmimeticthatinhibitsbothJAK1andJAK2withIC50valuesof2.7and4.5nM,respectivelyandislessselectiveforJAK3(IC50=322nM).
- AffectsDCdifferentiationandfunction,leADIngtoimpairedTcellactivation.
- Usedinthetreatmentofmyeloproliferativeneoplasmsandpsoriasis.
- Anticanceragent.Showntoinduceapoptosisandautophagy.
- PotentandselectiveinhibitorofHIV-1replicationandvirusreactivationinvitro.
ProductReferences
- EnantioselectivesynthesisofJanuskinaseinhibitorINCB018424viaanorganocatalyticaza-Michaelreaction:Q.Lin,etal.;Org.Lett.11,1999(2009)
- PreclinicalcharacterizationoftheselectiveJAK1/2inhibitorINCB018424:therapeuticimplicationsforthetreatmentofmyeloproliferativeneoplasms:A.Quintas-Cardama,etal.;Blood115,3109(2010)
- SelectiveinhibitionofJAK1andJAK2isefficaciousinrodentmodelsofarthritis:preclinicalcharacterizationofINCB028050:J.S.Fridman,etal.;J.Immunol.184,5298(2010)
- Ruxolitinib,aselectiveJAK1andJAK2inhibitorforthetreatmentofmyeloproliferativeneoplasmsandpsoriasis:R.A.Mesa;IDrugs13,394(2010)
- TheJAK-inhibitorruxolitinibimpairsdendriticcellfunctioninvitroandinvivo:A.Heine,etal.;Blood122,1192(2013)
- Specificityandmechanism-of-actionoftheJAK2tyrosinekinaseinhibitorsruxolitinibandSAR302503(TG101348):T.Zhou,etal.;Leukemia28,404(2014)
- TumoricidaleffectsoftheJAKinhibitorRuxolitinib(INC424)onhepatocellularcarcinomainvitro:G.S.Wilson,etal.;CancerLett.341,224(2013)
- INCB018424inducesapoptoticcelldeaththroughthesuppressionofpJAK1inhumancoloncancercells:H.J.An,etal.;Neoplasma61,56(2014)
- Ruxolitinibisapotentimmunosuppressivecompound:isittimeforanti-infectiveprophylaxis?A.Heine,etal.;Blood122,3843(2013)
- RuxolitinibandtofacitinibarepotentandselectiveinhibitorsofHIV-1replicationandvirusreactivationinvitro:C.Gavegnano,etal.;Antimicrob.AgentsChemother.58,1977(2014)
- Ruxolitinibinducesautophagyinchronicmyeloidleukemiacells:B.G.Bagca,etal.;TumourBiol.37,1573(2016)
品牌介绍
Adipogen公司由三个子公司组成，分别是Adipogen,Inc.(韩国),AdipogenSA(瑞士)和 AdipogenCorporation(美国圣地亚哥)。总部设在美国，运营总部在瑞士利斯塔尔。Adipogen公司专门从事生命科学研究试剂的开发，如癌症、免疫、炎症、代谢疾病（糖尿病、肥胖）、干细胞和神经退行性疾病等领域。其重点关注开发创新优质的ELISA试剂盒。另外，也可提供抗体和蛋白产品，Adipogen拥有自己的化学实验室，致力于开发创新型小分子化合物。
联络我们
